Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis (STELLAR 3)
Study description
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce progression to cirrhosis and associated complications in adults with NASH and bridging (F3) fibrosis.
Pathology
Non-alcoholic Statohepatitis NASH
Study type
Clinical trial
Status
Active
Study start date
2016
Funder Type
Industry funded study
Investigator
Dr. med. Alberto MORIGGIA
Recruitment
Completed